1. Scrip
  2. >>Business

Genmab On The Hunt For Late-Stage Assets

 
• By Kevin Grogan

The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.

Jan van de Winkel
Jan van de Winkel • Source: Genmab

Genmab A/S is looking to use some of its considerable cash pile built by burgeoning royalties from partners, notably Johnson & Johnson, to pick up promising later stage drugs that complement its internal R&D efforts.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.